Tapering Bupropion XL After 3 Years of Use
For patients on bupropion XL 300 mg daily, taper by reducing the dose to 150 mg once daily for a period before complete discontinuation. 1
FDA-Recommended Tapering Protocol
The FDA drug label provides explicit guidance for discontinuing bupropion XL:
- For patients on 300 mg daily: Decrease to 150 mg once daily prior to discontinuation 1
- Duration of taper: While the FDA label specifies dose reduction, it does not mandate a specific duration at the lower dose 1
Practical Tapering Approach
Given your patient's 3-year duration of treatment, a conservative approach is warranted:
- Week 1-2: Reduce from 300 mg to 150 mg once daily 1
- Monitor for withdrawal symptoms during this period, including irritability, anxiety, insomnia, headache, and generalized aches 2
- After 1-2 weeks at 150 mg: If tolerated without withdrawal symptoms, discontinue completely 1
Important Clinical Considerations
Withdrawal symptoms can occur with bupropion discontinuation, though they are less commonly discussed than with serotonergic antidepressants. 2 Case reports document irritable mood, anxiety, sleeplessness, headache, and generalized aches following abrupt cessation. 2
Monitor closely during the first 2 weeks after dose reduction, as this is when withdrawal symptoms typically peak if they occur. 3 The NCCN guidelines note that nicotine withdrawal symptoms (in smoking cessation contexts) peak within 1-2 weeks, and similar vigilance applies to medication discontinuation. 3
If withdrawal symptoms emerge, consider:
- Extending the duration at 150 mg for several additional weeks before attempting complete discontinuation 2
- Resuming the previous dose and attempting a slower taper 2
Key Caveats
The indication matters: If bupropion was prescribed for depression (particularly seasonal affective disorder), the FDA specifically recommends tapering in early spring for SAD patients. 1 For major depressive disorder, ensure the patient has been stable and reassess the need for continued treatment before discontinuing. 1
Bupropion has a relatively favorable discontinuation profile compared to SSRIs, as it lacks serotonergic activity and has a different mechanism of action (norepinephrine and dopamine reuptake inhibition). 4, 5 However, this does not eliminate withdrawal risk entirely. 2
Patient education is critical: Inform your patient about potential withdrawal symptoms and the importance of not abruptly stopping if symptoms occur. 2 Emphasize that any concerning symptoms should prompt immediate contact with your office rather than self-management.